Dori Thomas-Karyat

Dori Thomas-Karyat

Company: Synthis

Job title: Chief Executive Officer


Development of Immune Cell Targeted TGF-ß Therapies to Restore Tumor Clearance in Cancer Patients 4:15 pm

• In cancer patients, TGF-ß mediated immune suppression blocks tumor clearance • Blockade of TGF-ß signaling in immune cells is necessary and sufficient to rescue tumor clearance • At Synthis, we are developing first in class therapeutic platform to selectively and safely block TGF-ß mediated immune suppressionRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.